Gerhard Sissolak

Gerhard Sissolak

Auto-generated profile, based on publicly available information

Gerhard Sissolak

Department of Medicine, Division of Clinical Haematology, Stellenbosch University, South Africa

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2011 in BMC Public Health
Verified
Journal Article
Open access
PDF file
DSDagmar Sissolak
Dagmar Sissolak
FMFrederick Marais
Frederick Marais
SMShaheen Mehtar
Shaheen Mehtar
The tuberculosis (TB) epidemic in South Africa is characterised by one of the highest levels of TB/HIV co-infection and growing multidrug-resistant TB worldwide. Hospitals play a central role in the management of TB. We investigated nurses' experiences of factors influencing TB infection prevention and control (IPC) practices to identify risks associated with potential nosocomial transmission.

1 April 2006 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
RPRichard Pötter
Richard Pötter
JDJohannes Dimopoulos
Johannes Dimopoulos
BBBarbara Bachtiary
Barbara Bachtiary
GSGerhard Sissolak
Gerhard Sissolak
BKBeata Klos
Beata Klos
TKTomas-Hendrik Knocke-Abulesz
Tomas-Hendrik Knocke-Abulesz

6 September 2005 in Tropical Medicine & International Health
Verified
Journal Article
Closed access
PDF file
GSGerhard Sissolak
Gerhard Sissolak
PMPhilippe Mayaud
Philippe Mayaud

1 April 2011 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
EAE.A. Abayomi
E.A. Abayomi
ASA. Somers
A. Somers
RGR. Grewal
R. Grewal
GSG. Sissolak
G. Sissolak
FBF. Bassa
F. Bassa
LAL.W. Ayers
L.W. Ayers

1 September 2013 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
PWPieter de Witt
Pieter de Witt
DMDeborah J. MBChB Maartens
Deborah J. MBChB Maartens
TUThomas S. Uldrick
Thomas S. Uldrick
GSGerhard MBChB Sissolak
Gerhard MBChB Sissolak
Background: Long-term survival for patients with AIDS-related diffuse large B-cell lymphoma (DLBCL) is feasible in settings with available combination antiretroviral therapy (cART). However, given limited oncology resources, outcomes for AIDS-associated DLBCL in South Africa are unknown. Methods: We performed a retrospective analysis of survival in patients with newly diagnosed AIDS-related DLBCL treated at a tertiary teaching hospital in Cape Town, South Africa, with cyclophosphamide, doxorubicin, vincristine, and oral prednisone (CHOP) or CHOP-like chemotherapy (January 2004 until December 2010). HIV-related and lymphoma-related prognostic factors were evaluated. Results: Thirty-six patients evaluated; median age 37.3 years, 52.8% men, and 61.1% black South Africans. Median CD4 count 184 cells per microliter (in 27.8% this was <100 cells/μL), 80% high risk according to the age-adjusted International Prognostic Index. Concurrent Mycobacterium tuberculosis in 25%. Two-year overall survival (OS) was 40.5% (median OS 10.5 months, 95% confidence interval: 6.5 to 31.8). Eastern Cooperative Oncology Group performance status of 2 or more (25.4% vs 50.0%, P = 0.01) and poor response to cART (18.0% vs 53.9%, P = 0.03) predicted inferior 2-year OS. No difference in 2-year OS was demonstrated in patients coinfected with M. tuberculosis (P = 0.87). Conclusions: Two-year OS for patients with AIDS-related DLBCL treated with CHOP like regimens and cART is comparable to that seen in the United States and Europe. Important factors effecting OS in AIDS-related DLBCL in South Africa include performance status at presentation and response to cART. Patients with comorbid M. tuberculosis or hepatitis B seropositivity seem to tolerate CHOP in our setting. Additional improvements in outcomes are likely possible.

1 June 2014 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
BFBrian Thabile Flepisi
Brian Thabile Flepisi
PBPatrick Bouic
Patrick Bouic
GSGerhard Sissolak
Gerhard Sissolak
BRBernd Rosenkranz
Bernd Rosenkranz